TCM
IONS icon

Tekla Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Tekla Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$3.6M Hold
87,840
– – 0.14% 92
2023
Q1 		$3.14M Hold
87,840
– – 0.12% 97
2022
Q4 		$3.32M Hold
87,840
– – 0.13% 92
2022
Q3 		$3.88M Sell
87,840
-87,840
-50% -$3.7M 0.16% 88
2022
Q2 		$6.5M Hold
175,680
– – 0.26% 76
2022
Q1 		$6.51M Hold
175,680
– – 0.23% 81
2021
Q4 		$5.35M Sell
175,680
-146,841
-46% -$4.62M 0.17% 98
2021
Q3 		$10.8M Hold
322,521
– – 0.35% 70
2021
Q2 		$12.9M Buy
322,521
+106,150
+49% +$4.16M 0.42% 60
2021
Q1 		$9.73M Buy
216,371
+23,170
+12% +$1.29M 0.33% 75
2020
Q4 		$10.9M Hold
193,201
– – 0.38% 77
2020
Q3 		$9.17M Hold
193,201
– – 0.34% 70
2020
Q2 		$11.4M Hold
193,201
– – 0.43% 49
2020
Q1 		$9.13M Sell
193,201
-16,723
-8% -$932K 0.41% 48
2019
Q4 		$12.7M Buy
209,924
+23,680
+13% +$1.41M 0.48% 46
2019
Q3 		$11.2M Buy
186,244
+58,646
+46% +$3.82M 0.49% 51
2019
Q2 		$8.2M Buy
127,598
+17,878
+16% +$1.26M 0.33% 68
2019
Q1 		$8.91M Buy
109,720
+26,882
+32% +$1.73M 0.36% 60
2018
Q4 		$4.48M Hold
82,838
– – 0.19% 90
2018
Q3 		$4.27M Hold
82,838
– – 0.16% 101
2018
Q2 		$3.45M Sell
82,838
-82,839
-50% -$3.67M 0.13% 107
2018
Q1 		$7.3M Buy
165,677
+36,747
+29% +$1.87M 0.28% 79
2017
Q4 		$6.49M Buy
+128,930
New +$7.07M 0.25% 76
2015
Q4 		– Sell
-147,000
Closed -$5.94M – 146
2015
Q3 		$5.94M Buy
147,000
+48,800
+50% +$2.53M 0.21% 94
2015
Q2 		$5.65M Buy
+98,200
New +$6.24M 0.2% 84

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Tekla Capital Management's IONS Position: Q2 2023 in Review

Tekla Capital Management held its Ionis Pharmaceuticals (IONS) position steady in Q2 2023 at 87,840 shares worth $3.6M. The position accounts for 0.14% of the portfolio, ranked #92.

Tekla Capital Management first reported a position in IONS in Q2 2015 and has held it in 25 quarters since. The position peaked at $12.9M in Q2 2021. 305 funds tracked by Wall St. Rank hold IONS as of Q2 2023.

  • Tekla Capital Management held 87,840 shares of Ionis Pharmaceuticals worth $3.6M as of Q2 2023.
  • Tekla Capital Management left its Ionis Pharmaceuticals share count unchanged in Q2 2023.
  • Ionis Pharmaceuticals made up 0.14% of Tekla Capital Management's portfolio in Q2 2023, its #92 holding.
  • Tekla Capital Management first reported a position in Ionis Pharmaceuticals in Q2 2015 and has held it in 25 quarters since.
  • Tekla Capital Management's Ionis Pharmaceuticals position peaked at $12.9M in Q2 2021.
  • 305 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.